|
|
|||||||
Hematopoiesis |
From the Laboratory of Experimental Oncology D, National Cancer Research Institute, 16132-Genoa, Italy (CP, PC, AP); Laboratory of Tumor Immunology, San Raffaele Scientific Institute, 20132, Milan, Italy (MZ, MRZ)
Correspondence: Alessandro Poggi, PhD, MD, National Cancer Research Institute (IST) Genoa, Laboratory of Experimental Oncology D, Department of Translational Oncogenesis, Largo R. Benzi 10, 16132 Genoa, Italy. E-mail: alessandro.poggi{at}istge.it
Background and Objectives: Mesenchymal stem cells (MSC) have been proposed as a way to treat graft-versus-host disease based on their immunosuppressive effect. We analyzed whether regulatory T cells can be generated in co-cultures of peripheral blood mononuclear cells (PBMC) and MSC.
Design and Methods: MSC were obtained from the bone marrow of four healthy donors and nine patients with acute leukemia in complete remission following chemotherapy. Short-term (4 days) co-cultures of MSC and autologous or allogeneic PBMC were set up, the lymphocytes harvested and their regulatory activity assessed.
Results: Lymphocytes harvested from MSC-PBMC co-cultures strongly inhibit (up to 95%) mixed lymphocyte reaction (MLR), recall to alloantigen, and CD3- or phytohemagglutinin-induced lymphocyte proliferation. These lymphocytes, termed regulatory cells (Regc), were all CD45+CD2+ with variable proportions of CD25+ cells (range 40–75% n=10) and a minor fraction expressed CTLA4 (2–4%, n=10) or glucocorticoid-induced tumor necrosis factcor receptor-related gene (0.5–4% n=10). Both CD4+ and CD8+ Regc purified from MSC-PBMC co-cultures strongly inhibited lymphocyte proliferation at a 1:100 Regc:responder cell ratio. CD4+ Regc expressed high levels of forkhead box P3 (Foxp3) mRNA while CD8+ Regc did not. The effectiveness of Regc, whether CD4+ or CD8+, was 100-fold higher than that of CD4+CD25+high regulatory T cells. Regc were also generated from highly purified CD25– PBMC or CD4+ or CD8+ T cell subsets. Soluble factors, such as interleukin-10, transforming growth factor-ß and prostaglandin E2 did not appear to be involved in the generation of Regc or in the Regc-mediated immuno-suppressive effect. Furthermore, cyclosporine A did not affect Regc generation or the immunosuppression induced by Regc.
Interpretation and Conclusions: These findings indicate that powerful regulatory CD4+ or CD8+ lymphocytes are generated in co-cultures of PBMC with MSC. This strongly suggests that these regulatory cells may amplify the reported MSC-mediated immunosuppressive effect.
Key words: mesenchymal stem cells, regulatory CD4+ T cells, regulatory CD8+ T cells, lymphocyte triggering.
Related Article
Haematologica 2007 92: 872-877.
This article has been cited by other articles:
![]() |
R. Atoui, D. Shum-Tim, and R. C.J. Chiu Myocardial regenerative therapy: immunologic basis for the potential "universal donor cells". Ann. Thorac. Surg., July 1, 2008; 86(1): 327 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Parekkadan, A. W. Tilles, and M. L. Yarmush Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells Stem Cells, July 1, 2008; 26(7): 1913 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Locatelli, R. Maccario, and F. Frassoni Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders? Haematologica, July 1, 2007; 92(7): 872 - 877. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |